Goal Statement
The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to optimally assess the risk of patients with HR-positive/HER2-negative early breast cancer and select optimal individualized therapy for those with higher-risk disease.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Incorporate the evidence on the current use of Ki67 as a predictive and prognostic biomarker into clinical practice
- Identify patients with high-risk features who may benefit from the addition of CDK4/6 inhibitor therapy to endocrine therapy in the adjuvant setting
- Foster collaborative discussions and workflows between the oncology multidisciplinary team and patients to guide personalized treatment planning for HR-positive/HER2-negative early breast cancer
- Promote strategies to ensure optimal adherence and persistence to prescribed oral CDK4/6 inhibitors in patients with early-stage breast cancer
- Manage adverse events associated with oral targeted therapy in the adjuvant setting for patients with HR-positive/HER2-negative breast cancer
Blanca Ledezma, MSN, NP – AOCNP
Nurse Practitioner
Hematology/Oncology
UCLA Health
Goal Statement
The goal of this activity is to improve learners’ knowledge, competence, and performance in applying practice-changing clinical data and expert recommendations to integrate the use of currently available therapies for their patients with metastatic prostate cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Evaluate novel therapeutically actionable molecular targets that hold promise as predictive or prognostic biomarkers for patients with metastatic prostate cancer
- Plan optimal, individualized sequential therapeutic strategies for metastatic prostate cancer, considering all available agents, clinical data including novel imaging techniques, and expert recommendations
- Counsel patients with metastatic prostate cancer on available therapies, taking into consideration patient preferences regarding differences in administration and safety profiles, as well as comorbidities and patient goals
- Identify patients with metastatic prostate cancer who may be eligible for enrollment on ongoing clinical studies investigating novel regimens
Teresa Knoop, RN
Copyright 2023 GLAONS All rights reserved.
Chuck Dukas
OCS 2023
Master of Ceremonies and Host
Heather McArthur, MD, MPH
Dr. Robert Lentz, MD
Learning Objectives
- Examine the rationale for using asparaginase in the treatment of pediatric and adult/young adult acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) as well as other disease states.
- Appraise key clinical trial data of different asparaginase-containing regimens in ALL/LBL and apply that knowledge to selection of optimal asparaginase-containing treatment, based on patient-specific factors as well as the latest data.
- Identify the different asparaginase products available, and distinguish them based upon dose, route, formulation, proper monitoring, PK profiles, and unique safety concerns.
- Recognize asparaginase related toxicities that lead to poorer patient prognosis, identify the difference between asparaginase infusion reactions and clinical/subclinical hypersensitivity, develop monitoring/interpretation strategies for serum asparaginase levels to optimize treatment, and understand silent inactivation.
- Using a case-based approach, formulate clinical strategies for asparaginase-containing regimens, focusing on efficacy and safety of different formulations, and practice approaches to monitor asparaginase levels while also preventing and mitigating asparaginase-related toxicities.
Brenda Martone, MSN, ANP-BC, AOCNP
Goal Statement
The goal of this activity is to educate oncologists, oncology nurses, pharmacists, and other healthcare professionals, as well as patients/caregivers, about recent developments in the care of gynecologic malignancies and to raise awareness of disparities in care to optimize and individualize the treatment experience for every patient.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Plan individualized treatment strategies for patients with cervical, endometrial, and ovarian cancers, considering the available clinical data, expert recommendations, and patient preferences
- Select maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings
- Individualize immune checkpoint inhibitor–based therapy in endometrial and cervical cancer based on unique tumor and patient characteristics
- Use available resources to effectively communicate with patients the risk factors and importance of screening, the therapeutic and prognostic implications for evidence-based molecular profiling, and the benefits of clinical trial enrollment
- Identify populations of patients who are at increased risk for poor prognosis and proactively provide inclusive education and support throughout all stages of diagnostic and treatment regimens
- Implement evidence-based supportive care for treatment-related symptoms experienced by patients with gynecologic cancers
PRESENTERS
Click on each link below for a printable file.
David Page, MD
Sandra Kurtin, PhD, ANP-C, AOCN
Dana M. Chase, MD, FACOG
Associate Professor
Division of Gynecologic Oncology
Department of Obstetrics & Gynecology
David Geffen School of Medicine at UCLA
Goal Statement
The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in understanding and applying the latest science and clinical trial data on current and emerging immuno-oncology therapies in earlier stages of cancer into clinical practice.
Learning Objectives:
- Assess the biologic rationale for the use of immuno-oncology in earlier stages of cancer, considering the available clinical data, impact on tumor natural history, and immune-related implications.
- Evaluate clinical trial data and endpoints, including survival surrogates, on the use of immune checkpoint as neoadjuvant/adjuvant therapy to inform patients earlier stages of cancer on the potential long-term benefits of this therapeutic strategy
- Identify patients with early-stage solid cancers who would be appropriate for treatment or clinical trial enrollment with immune checkpoint inhibitors in the neoadjuvant, adjuvant, or maintenance/consolidation setting based on recurrence risk, surgical considerations, biomarkers, risk–benefit considerations, as well as potential disparities (socio-economic, racial, and age) in care
- Identify and manage common and serious immune-related adverse events associated with immuno-oncology agents in early stages of cancer
Nazy Zomorodian, RNC, MSN, CUNP, CCRC, is a nurse practitioner in the Department of Urology at the University of California Los Angeles (UCLA) Medical Center, where she is also the Director of Genitourinary (GU) Clinical Trials. In addition, she is an Assistant Professor of Urology at the David Geffen School of Medicine at UCLA and is certified by the Association of Clinical Research Professionals as a Clinical Research Coordinator. Ms. Zomorodian specializes in the treatment of patients with genitourinary malignancies, including kidney, prostate, and bladder cancer, and her research focuses on developing novel therapeutics and improving outcomes for patients with these diseases.
Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to assess new and emerging GI biomarkers and to integrate biomarker findings into the planning of individualized treatments for patients with gastrointestinal malignancies.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Apply best practices for molecular testing in GI cancers, including the use of tissue-based biomarker testing for evaluation of BRAF V600E, HER2, HER3, BRCA1/2, FGFR2, IDH1, and histology-agnostic markers
- Discuss with patients the available clinical data and how predictive biomarkers can be used to guide therapy decisions in GI cancers
- Plan individualized therapeutic strategies for patients with GI malignancies based on predictive biomarker assessment
- Identify patients with GI malignancies who are appropriate for enrollment on ongoing clinical trials investigating novel biomarker-driven treatment strategies in GI malignancies
Learning Objectives
- Discuss how the mechanisms of action of immunotherapies influence their safety profile
- Identify risk factors predisposing patients to IRAEs
- Distinguish IRAEs from chemotherapy- and targeted therapy-related adverse events
- Coordinate with the interdisciplinary health care team to apply evidence-based guidelines and best practices in personalized nursing management plans for patients with IRAEs
- Develop patient counseling strategies promoting awareness, self-monitoring, and escalated reporting of IRAEs